Despite the historical adoption and reimbursement challenges for PGx testing firms, Myriad said it would try to achieve value-based pricing for Assurex's GeneSight test.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
Firalis is developing an assay based on HTG's EdgeSeq platform to identify rheumatoid arthritis patients likely to respond to anti-TNF-alpha therapies.
Certain bacterial species appear more common in gut microbiomes of individuals with MS, coinciding with inflammation-related gene expression in host blood.
The company said it has enlisted 23 academic and medical institutions to supply patient samples that will support the validation and launch of its tests.
The firm has not disclosed the specific disease the test will address but has determined this space represents the best opportunity for its array technology.
The new study in NEJM describes six families that share a disorder caused by mutations in IKAROS, a protein that plays a role in immune cell development.
The approach can increase CpG coverage about 18-fold by inferring from existing data to predict methylation of sites outside those covered on the arrays themselves.
